Leukemia Research Reports最新文献

{"title":"5-AZACITIDINE IN HIGH RISK MYELODYSPLASTIC SYNDROME-SINGLE CENTER EXPERIENCE","authors":"I. Mandac Smoljanovic,&nbsp;M. Grzelja","doi":"10.1016/j.lrr.2024.100442","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100442","url":null,"abstract":"<div><h3>Introduction</h3><p>Myelodysplastic syndrome (MDS) represents a group of malignant clonal hematological disorders characterized by dysplasia in one or more hematopoietic lineages in the bone marrow, leading to cytopenias and an increased risk of developing acute myeloid leukemia. The only treatment option that has shown benefit in PFS and OS for high-risk MDS is 5-azacitidine (5-AZA).</p></div><div><h3>Methods</h3><p>The aim of this study was to determine the impact of 5-AZA on the treatment outcome of patients with high-risk MDS from January 1, 2013, to December 31, 2021, at the Clinical Hospital Merkur in Zagreb, Croatia. Retrospective analysis was performed on data from patients with high-risk MDS. The study included 38 patients (M:F=25:13), at time of study conclusion, 34 patients died. Laboratory data and overall survival of the patients were analyzed. Data were analyzed using the Kaplan-Meier method, Log-rank test, and Mann-Whitney U test.</p></div><div><h3>Results</h3><p>A longer overall survival was observed in patients treated with more than 12 cycles of 5-AZA. The median survival of the group receiving more than 12 cycles of 5-AZA was 24 months, while the median survival of patients receiving less than 12 cycles was 11 months (p=0.023). Higher creatinine levels at diagnosis and lower LDH levels before the first cycle were observed in the group of surviving patients.</p></div><div><h3>Conclusions</h3><p>The results of this study highlight the efficacy of 5-AZA in the first-line treatment of high-risk MDS patients, with a statistically significant difference in overall survival observed in group of HR MDS patients receiving at least 12 cycles of 5-AZA.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100442"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000323/pdfft?md5=dd7b44a00b9e87af9c4f5d608a9d6f8e&pid=1-s2.0-S2213048924000323-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Posterior reversible encephalopathy syndrome (PRES) and myeloma","authors":"Ricardos Ghanem ,&nbsp;Sylvie Glaisner ,&nbsp;Arthur Bobin ,&nbsp;Anne-Marie Ronchetti ,&nbsp;Sophie Cereja ,&nbsp;Bertrand Joly ,&nbsp;Célia Salanoubat ,&nbsp;Guillemette Fouquet","doi":"10.1016/j.lrr.2023.100407","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100407","url":null,"abstract":"<div><p>Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment. Although rare, we must remain vigilant about PRES in myeloma patients. Stricter control of blood pressure could limit its occurrence.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100407"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221304892300047X/pdfft?md5=79ce5915187d635342b88c18f8a34c3e&pid=1-s2.0-S221304892300047X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139100131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic heterogeneity within B/T mixed phenotype acute leukemia in a context of an immunophenotype","authors":"Ruifang Zheng ,&nbsp;Franklin Fuda ,&nbsp;Jeffrey R. Gagan ,&nbsp;Olga K. Weinberg ,&nbsp;Prasad Koduru ,&nbsp;Miguel Cantu ,&nbsp;Kathleen Ludwig ,&nbsp;Jamie M. Truscott ,&nbsp;Robert Collins ,&nbsp;Stephen Chung ,&nbsp;Yazan F. Madanat ,&nbsp;Weina Chen","doi":"10.1016/j.lrr.2023.100410","DOIUrl":"https://doi.org/10.1016/j.lrr.2023.100410","url":null,"abstract":"<div><p>B/T mixed phenotype acute leukemia (MPAL) is a rare aggressive leukemia. Three cases of B/T MPAL were identified with comprehensive immunophenotypic, cytogenetic, and molecular studies. T-lineage predominant B/T MPAL shares a genetic signature with T-ALL whereas B/T lineage co-dominant B/T MPAL lacks such a T-ALL signature<em>.</em> All three patients were treated with lineage-matched-ALL therapy and alive at the last follow-up. Our study is the first to demonstrate molecular heterogeneity within B/T MPAL in a context of an immunophenotype of T-lineage versus B-lineage predominance. The implication of such a phenotype-genotype association on diagnostic classification is briefly discussed.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100410"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221304892300050X/pdfft?md5=dc5984f2e902dbb90e8b9e1ad03a0cf8&pid=1-s2.0-S221304892300050X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139108502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of AML using non-intensive chemotherapy in Jehovah's Witness patients","authors":"David Page,&nbsp;Daniel Sawler,&nbsp;Joseph Brandwein","doi":"10.1016/j.lrr.2024.100477","DOIUrl":"10.1016/j.lrr.2024.100477","url":null,"abstract":"<div><p>Acute myeloid leukemia (AML) patients undergoing induction chemotherapy receive transfusion support to manage severe cytopenias and associated sequelae. Jehovah's Witness (JW) patients typically decline transfusion of most or all blood products. This can lead to exclusion of JW patients from otherwise life-saving treatments due to safety concerns. We present two cases demonstrating the successful induction of JW patients without the need for red cell or platelet transfusion support; the first, an older AML patient induced with azacitidine &amp; venetoclax; the second, a patient with acute promyelocytic leukemia induced using arsenic trioxide and all-trans retinoic acid. Both patients required modifications to the induction regimens to accommodate their wishes. These cases support growing evidence that selected JW patients with AML can be successfully treated using appropriate accommodations.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100477"},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000670/pdfft?md5=a4e1f10b090b2b1a38c29e7419937478&pid=1-s2.0-S2213048924000670-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141985311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report","authors":"E. Amabile,&nbsp;F. Fazio,&nbsp;M. Martelli,&nbsp;MT. Petrucci","doi":"10.1016/j.lrr.2024.100491","DOIUrl":"10.1016/j.lrr.2024.100491","url":null,"abstract":"<div><div>POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M–protein, skin changes syndrome) is a rare condition due to an underlying plasma cell neoplasm whose clinical presentation can be various so it could lead to delayed diagnosis and treatment. The pathogenesis of the syndrome is not well understood, and its therapy is adapted from other plasma cell disorders with the aim of alleviating symptoms, decreasing end-organ damage, improving quality of life and prolonging overall survival. We report a case of a 71 years-old woman who has been treated with continuous DRd (daratumumab, lenalidomide and dexamethasone) scheme.</div></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100491"},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of a CLL associated IgM hyper-viscosity syndrome: A rare case","authors":"Toufic Tannous ,&nbsp;Gil Hevroni ,&nbsp;Raiyan Islam ,&nbsp;Georgios Pongas","doi":"10.1016/j.lrr.2024.100479","DOIUrl":"10.1016/j.lrr.2024.100479","url":null,"abstract":"<div><p>In the context of chronic lymphocytic leukemia (CLL), Hyperviscosity Syndrome (HVS) typically arises from hyperleukocytosis, although it infrequently stems from IgM hyperparaproteinemia. We present a distinctive case of HVS induced by IgM hyperparaproteinemia in a patient experiencing relapsed CLL, marked by bulky disease and cytopenias upon progression. The patient exhibited new symptoms, including headache, dizziness, and confusion. Laboratory analysis revealed an elevated total protein level, and serum electrophoresis identified an elevated M spike at 4 g/dL with IgM on immunofixation. Suspecting HVS, prompt plasmapheresis was initiated, resulting in symptom resolution within two days.</p><p>A comprehensive literature review suggests that CLL patients with an elevated IgM level often face a poor prognosis, though HVS symptoms are not commonly observed. Our case underscores the significance of swiftly identifying HVS when IgM hyperparaproteinemia is detected in CLL patients. Notably, our patient not only achieved successful treatment for the acute presentation but also initiated second-line therapy for relapsed disease. In conclusion, effective management and stabilization of CLL patients with IgM-associated HVS are attainable, emphasizing the crucial role of prompt recognition.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"22 ","pages":"Article 100479"},"PeriodicalIF":0.7,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000694/pdfft?md5=5e85418b438fce9432b4f1809324a226&pid=1-s2.0-S2213048924000694-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 95-year-old patient suffered high-grade B-cell lymphoma combined hairy cell leukemia","authors":"Lingli Wang ,&nbsp;Jing Wang ,&nbsp;Min Li ,&nbsp;Lei Tian","doi":"10.1016/j.lrr.2024.100457","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100457","url":null,"abstract":"<div><p>This case report discusses a 95-year-old man diagnosed with two types of lymphomas. He was hospitalized for erysipelas in September 2018. The lymph node revealed high-grade B-cell lymphoma with Myc and Bcl-2 rearrangement. Bone marrow biopsy revealed hairy cell leukemia, a rare type of indolent B-cell lymphoma. We found that the bone marrow and left inguinal lymph node were non-homologous. There are no known reports of super-aged patients with two types of lymphoma simultaneously. The toxicity of R-CHOP in elderly people limited its usage, so we first chose rituximab. However, this approach was not successful. We then considered the Bruton tyrosine kinase (BTK) inhibitor, but its use was limited due to high blood pressure. Finally, we administered venetoclax, which the patient took for 2 years. The results of the routine blood examination were close to normal and no enlarged superficial or abdominal lymph nodes were observed.This is the oldest reported patient with two types of malignant lymphatic diseases. Additionally, this rare case suggests that targeted therapy can be more effective and safe for super-aged individuals. To summarize, a 95-year-old man diagnosed with two types of lymphomas, high-grade B-cell lymphoma and hairy cell leukemia, was successfully treated with venetoclax after other treatments failed. This case suggests that targeted therapy can be effective and safe for super-aged patients with multiple malignant lymphatic system diseases.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100457"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000475/pdfft?md5=c400f23e6944029eca93b5743974a2be&pid=1-s2.0-S2213048924000475-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140295824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extramedullary plasmacytoma of the orbit complicating the evolution of multiple myeloma in complete remission","authors":"Nader Slama ,&nbsp;Inaam Bizid ,&nbsp;Ahlem Bellalah ,&nbsp;Mabrouk Abdelali ,&nbsp;Mohamed Adnene Laatiri","doi":"10.1016/j.lrr.2024.100460","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100460","url":null,"abstract":"<div><p>Orbital plasmacytoma is rare and has only been reported in the context of the initial diagnosis of multiple myeloma. Moreover, isolated orbital plasmacytoma without any signs of multiple myeloma is extremely rare.</p><p>We report the case of a 59-year-old female patient diagnosed with IgA Kappa multiple myeloma. It was stage I ISS (International Staging System) and stage I R-ISS (Revised ISS). According to the Tunisian national protocol, the patient was included in the standard-risk group and was eligible for four cycles of CTD (Cyclophosphamide, Thalidomide, Dexamethasone) followed by autologous stem cell transplantation. Taking into account the partial response after the CTD cycles, the patient has benefited from two VTD cycles (Bortezomib, Thalidomide, Dexamethasone). Thus, complete remission was obtained. The patient refused autologous stem cell transplantation. Therefore, maintenance treatment based on Thalidomide only was started and received over a twelve-month period.</p><p>Five months after the end of maintenance treatment, she reported frontal headaches that were resistant to symptomatic treatment, with ptosis in the right eye in physical examination. Brain MRI revealed the presence of a right cranio-orbital tissue mass with intra-orbital and extra-axial cerebral components. The mass measured 32/36 mm on axial sections and 47 mm in height. The patient underwent a complete resection of the cranio-orbital mass with cranioplasty. The histopathological examination of the mass with Immunohistochemistry staining confirmed the diagnosis of orbital plasmocytoma.</p><p>An update of the multiple myeloma assessment did not reveal any biological, cytological or radiological signs in favor of multiple myeloma. Therefore the diagnosis of isolated orbital plasmacytoma without signs of multiple myeloma was made.</p><p>Post-operative brain MRI showed complete disappearance of the right cranio-orbital tissue lesion. There was only a persistent meningeal enhancement of the dura mater at the surgical site, suggestive of post-operative changes. The patient was then referred for cranio-orbital radiotherapy.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100460"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000505/pdfft?md5=6b41ef9dd4242995d540915531566917&pid=1-s2.0-S2213048924000505-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140646740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PATHOGENIC MECHANISMS OF DDX41 MUTATIONS IN THE DEVELOPMENT OF MYELOID MALIGNANCIES","authors":"A. Kon ,&nbsp;M. Nakagawa ,&nbsp;A. Tomita ,&nbsp;K. Kataoka ,&nbsp;N. Kakiuchi ,&nbsp;H. Makishima ,&nbsp;M. Nakayama ,&nbsp;H. Koseki ,&nbsp;Y. Nannya ,&nbsp;S. Ogawa","doi":"10.1016/j.lrr.2024.100425","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100425","url":null,"abstract":"<div><h3>Introduction</h3><p>Germline <em>DDX41</em> variants are implicated in late-onset myeloid neoplasms, accounting for the largest germline risk of the development of myeloid neoplasms. In typical cases, a germline loss-of-function allele is compounded by the somatic R525H mutation affecting the helicase domain in the remaining allele. The molecular mechanism by which <em>DDX41</em> mutations lead to myeloid neoplasms remains to be elucidated.</p></div><div><h3>Methods</h3><p>To delineate the pathogenic mechanism of <em>DDX41</em>-mutated myeloid neoplasms, we generated mice models carrying the conditional <em>Ddx41</em> knock-out and/or R525H knock-in alleles.</p></div><div><h3>Results</h3><p>In non-competitive bone marrow (BM) transplantation, most of the mice reconstituted with <em>Ddx41</em>^−/− or <em>Ddx41</em>^R525H/− BM died within a month due to severe BM failure. In competitive transplantation, <em>Ddx41</em>^−/− and <em>Ddx41</em>^R525H/− mice-derived cells showed markedly disadvantageous reconstitution, while <em>Ddx41</em>^+/− and <em>Ddx41</em>^R525H/+ mice-derived cells showed slightly reduced reconstitution compared to <em>Ddx41</em>^+/+ mice-derived cells. By contrast, the mice transplanted with <em>Ddx41</em>^+/− or <em>Ddx41</em>^R525H/+ BM showed significantly reduced WBC counts and anemia in long-term observation in both primary and serial transplantations. Some of the <em>Ddx41</em>^+/− or <em>Ddx41</em>^R525H/+ BM-transplanted mice exhibited MDS-like phenotypes, showing ineffective hematopoiesis with evidence of erythroid dysplasia. Transcriptome analysis of <em>Ddx41</em>^+/− and <em>Ddx41</em>^R525H/+ derived stem cells exhibited a significant deregulation of genes involved in RNA metabolism, ribosome biogenesis and apoptosis.</p></div><div><h3>Conclusions</h3><p>Monoallelic <em>Ddx41</em> loss-of function or R525H knock-in alleles led to age-dependent impaired hematopoiesis and the development of myeloid malignancies, while compound biallelic loss-of function and R525 alleles showed a severely compromised function of hematopoietic stem cells.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100425"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000153/pdfft?md5=fedf7d34fa8db23043870c6d996d5179&pid=1-s2.0-S2213048924000153-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CYTOGENOMIC PROFILING OF LARGE COHORT OF INDIAN MYELODYSPLASTIC SYNDROMES","authors":"N. Maurya ,&nbsp;C. Shanmukhaiah ,&nbsp;M. Madkaikar ,&nbsp;B.R. Vundinti","doi":"10.1016/j.lrr.2024.100427","DOIUrl":"https://doi.org/10.1016/j.lrr.2024.100427","url":null,"abstract":"<div><h3>Introduction</h3><p>About 40% - 50% of Myelodysplastic syndromes (MDS) patients present with a normal karyotype whereas 50% - 60% of patients are of low risk, however, they tend to have worse outcomes and a higher chance of disease progression. Hence, we aim to study the genomic pathophysiology of disease and their association with overall survival in MDS.</p></div><div><h3>Methods</h3><p>The study cohort included 200 MDS patients. The molecular cytogenetic and mutation profiling was carried out in all MDS patients. The patients were clinically followed up. The Kaplan-Meier survival and multivariate analysis was performed using GraphPad Prism 5.00</p></div><div><h3>Results</h3><p>The WHO 2016 classification revealed a high frequency of MDS – MLD (33%) followed by MDS – SLD (25%), MDS – EB-1/2 (24%). The chromosomal aberrations were identified in 35% of MDS patients by CK/FISH. The NGS identified gene mutations in 75% of the cohort. The survival analysis revealed that the mutations in <em>TP53, JAK2/3, KRAS, NRAS</em>, and <em>ASXL1</em> are significantly (<em>P</em> &lt; 0.05) associated with poor survival. SNP array analysis (n=77), revealed, patients with chromosome 2 aberrations have a poor prognosis. SNP array combined with NGS confirmed the biallelic loss of function of the TP53 gene (3/7), a clinically relevant biomarker and new genetic-based MDS entity i.e. MDS-biTP53 as per the new WHO classification 2022. The univariate and multivariate analysis suggested that genetic lesions (mutations/CNVs/LOH) with IPSS-R could be prognosticating markers in MDS patients.</p></div><div><h3>Conclusions</h3><p>Our study strongly supports that the genome profiling by combined CGH+SNP array and NGS improves prognostication and hence personalized disease management.</p></div>","PeriodicalId":38435,"journal":{"name":"Leukemia Research Reports","volume":"21 ","pages":"Article 100427"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213048924000177/pdfft?md5=0a96e00835b0036ad839333d54d0b25f&pid=1-s2.0-S2213048924000177-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140103292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}